Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotox...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/9/1762 |
| _version_ | 1827657833601040384 |
|---|---|
| author | Guohao Liu Yanmei Qiu Po Zhang Zirong Chen Sui Chen Weida Huang Baofeng Wang Xingjiang Yu Dongsheng Guo |
| author_facet | Guohao Liu Yanmei Qiu Po Zhang Zirong Chen Sui Chen Weida Huang Baofeng Wang Xingjiang Yu Dongsheng Guo |
| author_sort | Guohao Liu |
| collection | DOAJ |
| description | Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotoxic or myeloablative chemotherapy. Immunotherapy presents exciting therapeutic opportunities against DIPG that is characterized by unique and heterogeneous features. However, the non-inflammatory DIPG microenvironment greatly limits the role of immunotherapy in DIPG. Encouragingly, the induction of immunogenic cell death, accompanied by the release of damage-associated molecular patterns (DAMPs) shows satisfactory efficacy of immune stimulation and antitumor strategies. This review dwells on the dilemma and advances in immunotherapy for DIPG, and the potential efficacy of immunogenic cell death (ICD) in the immunotherapy of DIPG. |
| first_indexed | 2024-03-09T22:51:28Z |
| format | Article |
| id | doaj.art-8e9b0ecf0cb9435fa44f54250448c55b |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T22:51:28Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-8e9b0ecf0cb9435fa44f54250448c55b2023-11-23T18:20:02ZengMDPI AGPharmaceutics1999-49232022-08-01149176210.3390/pharmaceutics14091762Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical StudiesGuohao Liu0Yanmei Qiu1Po Zhang2Zirong Chen3Sui Chen4Weida Huang5Baofeng Wang6Xingjiang Yu7Dongsheng Guo8Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of General Surgery, Jinshan Hospital, Fudan University, Shanghai 200433, ChinaDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, ChinaDiffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotoxic or myeloablative chemotherapy. Immunotherapy presents exciting therapeutic opportunities against DIPG that is characterized by unique and heterogeneous features. However, the non-inflammatory DIPG microenvironment greatly limits the role of immunotherapy in DIPG. Encouragingly, the induction of immunogenic cell death, accompanied by the release of damage-associated molecular patterns (DAMPs) shows satisfactory efficacy of immune stimulation and antitumor strategies. This review dwells on the dilemma and advances in immunotherapy for DIPG, and the potential efficacy of immunogenic cell death (ICD) in the immunotherapy of DIPG.https://www.mdpi.com/1999-4923/14/9/1762diffuse intrinsic pontine gliomaimmune microenvironmentimmunotherapyimmunogenic cell deathdamage associated molecular patterns |
| spellingShingle | Guohao Liu Yanmei Qiu Po Zhang Zirong Chen Sui Chen Weida Huang Baofeng Wang Xingjiang Yu Dongsheng Guo Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies Pharmaceutics diffuse intrinsic pontine glioma immune microenvironment immunotherapy immunogenic cell death damage associated molecular patterns |
| title | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
| title_full | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
| title_fullStr | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
| title_full_unstemmed | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
| title_short | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
| title_sort | immunogenic cell death enhances immunotherapy of diffuse intrinsic pontine glioma from preclinical to clinical studies |
| topic | diffuse intrinsic pontine glioma immune microenvironment immunotherapy immunogenic cell death damage associated molecular patterns |
| url | https://www.mdpi.com/1999-4923/14/9/1762 |
| work_keys_str_mv | AT guohaoliu immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT yanmeiqiu immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT pozhang immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT zirongchen immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT suichen immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT weidahuang immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT baofengwang immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT xingjiangyu immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT dongshengguo immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies |